Ac-CoA Synthase Inhibitor1 is a potent, reversible, acetate-dependent acetyl-CoA synthetase 2 (ACSS2) inhibitor with an IC50 value of 0.6μM[1]. Ac-CoA Synthase Inhibitor1 is an antiviral agent that inhibits respiratory syncytial virus (RSV)[2]. In LPS- or OC43 virus-activated MaugO cells, Ac-CoA Synthase Inhibitor1 significantly reversed the inhibitory effect of acetate on IL-1β expression and production, and consequently eliminated the inhibitory effect of acetate on key molecules in the NLRP3 signaling pathway (including NLRP3, pro-IL-1β, cleaved IL-1β, and cleaved caspase-1)[3].
References:
[1] Comerford S A, Huang Z, Du X, et al. Acetate dependence of tumors[J]. Cell, 2014, 159(7): 1591-1602.
[2] Kanno T, Miyako K, Endo Y. The diverse interaction of metabolism, immune response, and viral pathogens[J]. Frontiers in Immunology, 2025, 16: 1619926.
[3] Xu G, Zhou J, Liu K, et al. Macrophage-augmented intestinal organoids model virus-host interactions in enteric viral diseases and facilitate therapeutic development[J]. Nature Communications, 2025, 16(1): 4475.
Ac-CoA Synthase Inhibitor1是一种有效的可逆的醋酸盐依赖性乙酰辅酶A合成酶2（ACSS2）抑制剂，IC50值为0.6μM[1]。Ac-CoA Synthase Inhibitor1是一种抗病毒剂，能够抑制呼吸道合胞病毒（RSV）[2]。Ac-CoA Synthase Inhibitor1在LPS或OC43病毒激活的MaugO细胞中，显著逆转了乙酸对IL-1β表达和产生的抑制效应，并随之消除了乙酸对NLRP3信号通路中关键分子（包括NLRP3、前体IL-1β、裂解型IL-1β和裂解型caspase-1）的抑制作用[3]。